Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ocular Therapeutix (OCUL) PT Raised to $11 at Raymond James
December 3, 2018 1:20 PM ESTRaymond James analyst Dane Leone raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $11.00 (from $10.00) while maintaining a Strong Buy rating following FDA approval.
... MoreOcular Therapeutix (OCUL) Announces FDA Approval of DEXTENZA for Treatment of Ocular Pain
December 3, 2018 7:01 AM ESTOcular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery.
We are extremely pleased to announce the approval of DEXTENZA, coming so soon after our pre-approval inspection and... More
